NCT00737555已完成1 期
A Phase 1b Dose-escalation Study to Evaluate the Safety and Tolerability of the Addition of the Aminopeptidase Inhibitor CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours
Chroma Therapeutics2 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2006年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 23
- 试验地点
- 2
- 主要终点
- To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered in combination with paclitaxel.
研究概览
简要总结
The treatment of cancer often involves the use of more than one drug at the same time. In this study, patients are treated with the already marketed drug paclitaxel (administered every 3 weeks by infusion)and with the investigational drug CHR-2797 (given orally, once daily). The purpose of this study is to evaluate if it is safe to administer these two drugs together, and how well the combination is tolerated by patients. The first patients will receive a 90mg dose of CHR-2797; doses will be increased in subsequent patients, as long as they are adequately tolerated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed, informed consent.
- •Age > 18 years
- •Histologically or cytologically documented locally advanced or metastatic solid tumour refractory to standard therapy or for which no standard therapy exists.
- •Patients should have recovered from the acute adverse effects of prior therapies (excluding alopecia).
- •Adequate bone marrow, hepatic and renal function including the following:
- •Hb > 9g/dl (transfusion independent) or >10g/dl (transfusion permitted), absolute neutrophil count > 1.5 x 109/L, platelets ≥ 100 x 109/L;
- •Total bilirubin ≤ 1.5 x upper normal limit;
- •AST (SGOT), ALT (SGPT) ≤ 2.5 x upper normal limit
- •Creatinine ≤1.5 x upper normal limit.
- •Performance status (PS) ≤ 2 (ECOG scale).
- •Estimated life-expectancy greater than 3 months.
- •Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to start of trial. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment.
排除标准
- •Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to first dose of medication in this trial or within a longer period, depending on the defined characteristics of the agent e.g. 6 weeks for nitrosurea or mitomycin. Bisphosphonates for bone disease are permitted provided the doses are stable before and during the trial.
- •Co-existing active infection or serious concurrent illness.
- •Significant cardiovascular disease as defined by:
- •history of congestive heart failure requiring therapy;
- •history of unstable angina pectoris or myocardial infarction up to 6 months prior to trial entry;
- •presence of severe valvular heart disease;
- •presence of a ventricular arrhythmia requiring treatment.
- •Any co-existing medical condition that in the investigator's judgement will
- •substantially increase the risk associated with the patient's participation in the study.
- •Psychiatric disorders or altered mental status precluding understanding of the
- •informed consent process and/or completion of the necessary studies.
- •Gastrointestinal disorders that may interfere with absorption of the study drug.
- •Persistent grade II or greater toxicity from any cause.
- •Patients with known brain tumours or metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurologic and other adverse events.
- •More than 4 prior chemotherapy regimens.
研究组 & 干预措施
1
Experimental
Once daily oral administration of CHR-2797 ( escalating dose groups) in solid tumour patients receiving paclitaxel infusion every three weeks
干预措施: CHR-2797 (Drug)
结局指标
主要结局
To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered in combination with paclitaxel.
时间窗: 18 weeks
次要结局
- To evaluate the pharmacokinetic profile of the combination of CHR-2797 and paclitaxel and identify any pharmacokinetic interaction between the 2 agents.(After 1st and 2nd infusion of paclitaxel)
- To determine response and response duration, time to progressive disease or treatment failure during combination therapy and in those patients who continued beyond 18 weeks on monotherapy with CHR-2797.(Maximum duration of patient treatment ( combination followed by monotherapy) was 9 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
AS703569 and Gemcitabine Combination in Advanced MalignanciesPancreatic CancerNCT01097512Merck KGaA, Darmstadt, Germany66
已完成
1 期
Safety Study of ON 01910.Na in Combination With Irinotecan or OxaliplatinAdvanced Solid TumorsNCT00861328Traws Pharma, Inc.18
已完成
1 期
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid TumorsSolid TumorNCT01165905Traws Pharma, Inc.10
已完成
1 期
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid TumorsMalignant NeoplasmasSolid TumorsNCT01125891Traws Pharma, Inc.39
已完成
1 期
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MNDAmyotrophic Lateral SclerosisMotor Neuron DiseaseNCT02870634Collaborative Medicinal Development Pty Limited50